Summaries & Associations of Study Results
Levels from GMM-05 Water Disinfection Model (Bromodichloromethane)
Target Organs and Levels of Evidence
NTP GMM Report Number 05
Produced from Chemtrack Database 01/05/06
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY | ||
|---|---|---|---|---|---|---|
| WATER DISINFECTION MODEL (BROMODICHLOROMETHANE) 75-27-4 |
09/27/05 | SOLVENT. CHEMICAL INTERMEDIATE. FLAME RETARDANT. (TDB) SPECIAL INITIATIVE USING THE TRANSGENIC MOUSE MODEL IN METHODS DEVELOPMENT. | Gavage 0, 25, 50, OR 100 MG/KG | Battelle Columbus Laboratory | ||
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||||
| MICE:P53 +/- (C57BL/6) (26-WEEK) | ||||||
| Male Lesions: NO EVIDENCE | None | |||||
| Nonneoplastic effects: | KIDNEY: TUBULE DEGENERATION | |||||
| Female Lesions: NO EVIDENCE | None | |||||
| Nonneoplastic effects: | LIVER: HEPATOCYTE FATTY CHANGE | |||||
| MICE:P53 +/- (C57BL/6) (41-WK) | ||||||
| Male Lesions: NO EVIDENCE | None | |||||
| Nonneoplastic effects: | KIDNEY: TUBULE DEGENERATION | |||||
| Female Lesions: NO EVIDENCE | None | |||||
| Nonneoplastic effects: | LIVER: HEPATOCYTE FATTY CHANGE | |||||
| MICE:TGAC (FVB/N) HEMIZYGOUS (26-WEEK) | ||||||
| Male Lesions: | None | |||||
| Nonneoplastic effects: | KIDNEY: TUBULE DEGENERATION | |||||
| Female Lesions: | FORESTOMACH: MULTIPLE SQUAMOUS CELL PAPILLOMA 3/15 5/15 6/15 11/15 | |||||
| Nonneoplastic effects: | LIVER: HEPATOCYTE FATTY CHANGE; HEPATOCYTE CYTOPLASMIC VACUOLIZATION | |||||
| MICE:TGAC (FVB/N) HEMIZYGOUS (41-WK) | ||||||
| Male Lesions: | None | |||||
| Nonneoplastic effects: | KIDNEY: TUBULE DEGENERATION | |||||
| Female Lesions: | FORESTOMACH: MULTIPLE SQUAMOUS CELL PAPILLOMA 1/10 6/10 5/10 9/10 | |||||
| Nonneoplastic effects: | LIVER: HEPATOCYTE FATTY CHANGE; HEPATOCYTE CYTOPLASMIC VACUOLIZATION | |||||
| WATER DISINFECTION MODEL (BROMODICHLOROMETHANE) 75-27-4 |
09/27/05 | SOLVENT. CHEMICAL INTERMEDIATE. FLAME RETARDANT. (TDB) SPECIAL INITIATIVE USING THE TRANSGENIC MOUSE MODEL IN METHODS DEVELOPMENT. | Topical Application 0, 64, 128, OR 256 MG/KG | Battelle Columbus Laboratory | ||
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||||
| MICE:TGAC (FVB/N) HEMIZYGOUS (26-WK) | ||||||
| Male Lesions: | None | |||||
| Female Lesions: | None | |||||
| MICE:TGAC (FVB/N) HEMIZYGOUS (39-WK) | ||||||
| Male Lesions: | None | |||||
| Female Lesions: | None | |||||
| WATER DISINFECTION MODEL (BROMODICHLOROMETHANE) 75-27-4 |
09/27/05 | SOLVENT. CHEMICAL INTERMEDIATE. FLAME RETARDANT. (TDB) SPECIAL INITIATIVE USING THE TRANSGENIC MOUSE MODEL IN METHODS DEVELOPMENT. | Dosed-Water 0, 175, 350, OR 700 MG/L | Battelle Columbus Laboratory | ||
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||||
| MICE:P53 +/- (C57BL/6) (26-WEEK) | ||||||
| Male Lesions: NO EVIDENCE | None | |||||
| Nonneoplastic effects: | KIDNEY: TUBULE DEGENERATION | |||||
| Female Lesions: NO EVIDENCE | None | |||||
| Nonneoplastic effects: | LIVER: HEPATOCYTE FATTY CHANGE | |||||
| MICE:P53 +/- (C57BL/6) (42-WK) | ||||||
| Male Lesions: NO EVIDENCE | None | |||||
| Nonneoplastic effects: | KIDNEY: TUBULE DEGENERATION | |||||
| Female Lesions: NO EVIDENCE | None | |||||
| MICE:TGAC (FVB/N) HEMIZYGOUS (26-WEEK) | ||||||
| Male Lesions: | None | |||||
| Nonneoplastic effects: | KIDNEY: NEPHROPATHY; TUBULE DEGENERATION | |||||
| Female Lesions: | None | |||||
| Nonneoplastic effects: | LIVER: HEPATOCYTE FATTY CHANGE; HEPATOCYTE CYTOPLASMIC VACUOLIZATION | |||||
| MICE:TGAC (FVB/N) HEMIZYGOUS (42-WK) | ||||||
| Male Lesions: | None | |||||
| Nonneoplastic effects: | KIDNEY: NEPHROPATHY | |||||
| Female Lesions: | None | |||||
| Nonneoplastic effects: | LIVER: HEPATOCYTE FATTY CHANGE | |||||
Web page last updated on September 06, 2007
